InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,483.17
(
0.34%
)
US TECH 100
19,125.20
(
-0.43%
)
Dow Jones
39,543.35
(
1.00%
)
Brent Oil
85.12
(
1.31%
)
Bitcoin
61,228.72
(
-3.06%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 134

Wednesday, 05/02/2018 2:56:07 PM

Wednesday, May 02, 2018 2:56:07 PM

Post# of 438
KPTI read out Ph2b results that will warrant an NDA filing for selexinor, its treatment for penta-refractory multiple myeloma (MM)

The TAM for this treatment could produce up to $500mn in sales. MM is the third most common blood cancer in the U.S.

Selexinor's market advantage is that it is an oral treatment competing against for-the-most-part less safe treatments.

After these results, the company released plans to issue a $125mn stock offering.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up